Chemo plus camrelizumab before surgery for stage IB1 cervical cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests whether giving chemotherapy combined with camrelizumab (a drug that helps the immune system fight cancer) before surgery can help women with early-stage cervical cancer who want to preserve their fertility. It is for patients whose tumors show a protein called PD-L1.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage IB1 cervical cancer (confirmed by exam and MRI).
- Your cancer type is squamous cell carcinoma (the most common type).
- Your tumor has a protein called PD-L1 (a score of CPS 1 or higher).
- You are between 18 and 45 years old and have a strong desire to get pregnant in the future.
- You are in generally good health (able to do daily activities, good blood counts, and no active autoimmune diseases).
- You have not had chemotherapy, radiation, or other immune drugs before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if giving chemotherapy plus an immunotherapy drug before surgery can help shrink tumors and improve outcomes for patients with stage IB2 cervical cancer that has not been treated yet. It might be an option if you have a specific type of cervical cancer that shows a certain protein (PD-L1) on your tumor cells.
This trial tests whether combining chemotherapy with immunotherapy before surgery can help treat cervical cancer that is PD-L1 negative. It's for women with larger tumors (stage IB3 to IIB) who have not been treated yet.
This trial tests whether a combination of chemotherapy and immunotherapy (pembrolizumab) before surgery works better than standard chemoradiation for locally advanced cervical cancer. It may help shrink tumors more effectively.
This trial tests a combination of immunotherapy (AK104) and standard chemotherapy before surgery for a certain type of early-stage cervical cancer. The goal is to see if this approach can help shrink the tumor enough to allow fertility-preserving surgery, so you may be able to keep your uterus.
This trial tests a combination of chemotherapy and immunotherapy for patients with cervical cancer that has spread to pelvic lymph nodes (stage IIICp) after radical surgery. It aims to improve outcomes by boosting the immune system's ability to fight remaining cancer cells.
This study looks at whether giving chemotherapy before surgery (neoadjuvant chemotherapy) can shrink certain cervical cancers enough to allow fertility-sparing surgery. It may help some people avoid removing the uterus, while still treating the cancer effectively.
Hear when a new Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.